Company intelligence / Profile preview

Jasco Pharmaceuticals

Woburn, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Jasco Pharmaceuticals is developing JP11646, a novel, non-ATP-competitive PIM2 kinase inhibitor with promising anti-tumor efficacy in preclinical models of multiple myeloma. JP11646 demonstrated significant in vivo tumor suppression and survival benefit in animal models; clinical trials have not yet commenced.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

JP11646

Preclinical

Partnerships

Crown Bioscience

Beyond the preview

Go deeper on Jasco Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jasco Pharmaceuticals.

Explore the full profile